Neurological therapeutics developer Rodin took its overall funding to more than $30m after securing financing from Biogen and co-founder Atlas Venture.

Rodin Therapeutics, a US-based developer of treatments for neurological disorders, has received $17.3m from biotechnology company Biogen and venture capital firm Atlas Venture through a preferred stock financing.

Co-founded by Atlas Venture and biotech company Proteros Biostructures in 2013, Rodin is working on a pipeline of epigenetic modulators to combat neurological disorders such as Alzheimer’s disease.

In addition to providing equity financing, Rodin and Biogen have agreed a multi-year research collaboration centred on neuronal epigenetics. Biogen has also secured the…